Last Updated: September 25, 2026

ELUXADOLINE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for eluxadoline and what is the scope of patent protection?

Eluxadoline is the generic ingredient in two branded drugs marketed by Aurobindo Pharma, Zydus Pharms, and Abbvie, and is included in three NDAs. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound. There are two tentative approvals for this compound.

Summary for ELUXADOLINE
International Patents:153
US Patents:14
Tradenames:2
Applicants:3
NDAs:3
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 32
Clinical Trials: 10
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for ELUXADOLINE
What excipients (inactive ingredients) are in ELUXADOLINE?ELUXADOLINE excipients list
DailyMed Link:ELUXADOLINE at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ELUXADOLINE
Generic Entry Date for ELUXADOLINE*:
Constraining patent/regulatory exclusivity:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ELUXADOLINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Devintec SaglNA
AllerganPhase 3
Temple UniversityPhase 2/Phase 3

See all ELUXADOLINE clinical trials

Generic filers with tentative approvals for ELUXADOLINE
Applicant Application No. Strength Dosage Form
⤷  Start Trial⤷  Start Trial100MGTABLET;ORAL
⤷  Start Trial⤷  Start Trial75MGTABLET;ORAL
⤷  Start Trial⤷  Start Trial100MGTABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ELUXADOLINE
Paragraph IV (Patent) Challenges for ELUXADOLINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VIBERZI Tablets eluxadoline 75 mg and 100 mg 206940 6 2019-05-28

US Patents and Regulatory Information for ELUXADOLINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Abbvie VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Abbvie VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ELUXADOLINE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 ⤷  Start Trial ⤷  Start Trial
Abbvie VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 ⤷  Start Trial ⤷  Start Trial
Abbvie VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for ELUXADOLINE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Allergan Pharmaceuticals International Limited Truberzi eluxadoline EMEA/H/C/004098Truberzi is indicated in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS D). Withdrawn no no no 2016-09-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Supplementary Protection Certificates for ELUXADOLINE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1725537 2017C/003 Belgium ⤷  Start Trial PRODUCT NAME: ELUXADOLINE OF EEN FARMACEUTISCH AANVAARDBAAR ENANTIOMEER, DIASTEREOMEER, RACEMAAT OF EEN ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU1/16/1126 20160921
1725537 PA2017005,C1725537 Lithuania ⤷  Start Trial PRODUCT NAME: ELUKSADOLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINAS ENANTIOMERAS, DIASTEREOMERAS, RACEMATAS ARBA DRUSKA; REGISTRATION NO/DATE: EU/1/16/1126 20160919
1725537 122017000009 Germany ⤷  Start Trial PRODUCT NAME: ELUXADOLIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1126 20160919
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.